NCT02203006 (OVIHD) is a NA clinical trial of OVIHD in Patients Affected by the HIV, sponsored by Assistance Publique - Hôpitaux de Paris.

Who is sponsoring NCT02203006?

NCT02203006 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT02203006?

Interventions in NCT02203006: OVIHD.

What condition does NCT02203006 study?

NCT02203006 studies Patients Affected by the HIV.

Is NCT02203006 still recruiting?

NCT02203006 is currently active, enrolled. Last updated 30 April 2026.

Last reviewed 2026-04-30 · How we verify

NCT02203006: OVIHD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Constitution of an Open Monocentric Cohort of HIV Infected Patients

Active, enrolled NA Last updated 30 April 2026

What this trial tests

NA trial testing OVIHD in Patients Affected by the HIV in 1,613 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

19 October 2011

Primary endpoint
19 November 2030

19 November 2030

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	other
Enrollment	1,613
Start date	19 October 2011
Primary completion	19 November 2030
Estimated completion	19 November 2030
Sites	1 location across France

Drugs / interventions tested

OVIHD — full drug profile →

Conditions studied

Patients Affected by the HIV — all drugs for Patients Affected by the HIV →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with Patients Affected by the HIV. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

HIV infection
Time frame: 10 years
The HIV cohort will be constituted in collecting cardiovascular, neurological clinical data and medical past history (in case of women patient)

Sponsor's own description

The purpose of this study is to improve our knowledge concerning HIV infection, treated or not, in the current conditions of care to optimize it.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02203006 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 30 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02203006.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing